Paul Thomas - ABIOMED Independent Director
Director
Mr. Paul G. Thomas is an Independent Director of the Company. Mr. Thomas has served as a director since May 2011. Mr. Thomas served as the founder, president and Chief Executive Officer of Roka Bioscience, Inc. from September 2009 until his retirement in January 2017. Previously he served as Chairman, Chief Executive Officer, and President of LifeCell Corporation from October 1998 until it was acquired by KCI in August 2008. Prior to joining LifeCell, Mr. Thomas held various senior positions, including President of the Pharmaceuticals division, during a 15year tenure with Ohmeda Inc. Mr. Thomas currently serves on the Board of Directors of RTI Surgical. Mr. Thomas previously served as a member of the Board of Directors of Aegerion Pharmaceuticals, Inc. until its merger with Novelion Therapeutics Inc. in 2016 since 2011.
| Age | 61 |
| Tenure | 13 years |
| Professional Marks | MBA |
| Phone | 978 777-8411 |
| Web | www.abiomed.com |
ABIOMED Management Efficiency
The company has return on total asset (ROA) of 0.0955 % which means that it generated a profit of $0.0955 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1824 %, meaning that it created $0.1824 on every $100 dollars invested by stockholders. ABIOMED's management efficiency ratios could be used to measure how well ABIOMED manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 10 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. ABIOMED has a current ratio of 7.38, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ABIOMED until it has trouble settling it off, either with new capital or with free cash flow. So, ABIOMED's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ABIOMED sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ABIOMED to invest in growth at high rates of return. When we think about ABIOMED's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Vance Coffman | Amgen Inc | 71 | |
| Thomas Zeller | Black Hills | 70 | |
| John Mollenkopf | Antero Midstream Partners | 58 | |
| David Keyte | Antero Midstream Partners | 64 | |
| F Millner | Merit Medical Systems | N/A | |
| Gregory Garland | Amgen Inc | 60 | |
| Richard Connor | Antero Midstream Partners | 67 | |
| Tyler Jacks | Amgen Inc | 57 | |
| Scott Anderson | Merit Medical Systems | 70 | |
| Janiece Longoria | CenterPoint Energy | 64 | |
| Hisashi Hasegawa | HUTCHMED DRC | N/A | |
| Greg Garland | Amgen Inc | 56 | |
| Susan Rheney | CenterPoint Energy | 60 | |
| Wanda Austin | Amgen Inc | 63 | |
| Wendy Cloonan | CenterPoint Energy | 41 | |
| Jack Eugster | Black Hills | 69 | |
| Michael Howell | HUTCHMED DRC | 67 | |
| Francois Carbonnel | Amgen Inc | 69 | |
| Paul Korus | Antero Midstream Partners | 60 | |
| Tetsuo Katsurayama | HUTCHMED DRC | 58 | |
| Kenji Ohta | HUTCHMED DRC | 57 | |
Management Performance
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0955 |
ABIOMED Leadership Team
Elected by the shareholders, the ABIOMED's board of directors comprises two types of representatives: ABIOMED inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ABIOMED. The board's role is to monitor ABIOMED's management team and ensure that shareholders' interests are well served. ABIOMED's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ABIOMED's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Minogue, Chairman, CEO and President Member of Special Stock Option Committee and Member of Executive Committee | ||
| Paul Thomas, Independent Director | ||
| Andrew Greenfield, Vice President - Healthcare Solutions | ||
| Jeannine Rivet, Director | ||
| Ingrid Ward, Director Relations | ||
| Todd Trapp, CFO, Vice President | ||
| Christopher Gorder, Director | ||
| David Weber, Scientific Advisor | ||
| Ian McLeod, Principal Financial Officer, Principal Accounting Officer, Vice President Controller | ||
| Martin Sutter, Independent Director | ||
| Michael Howley, VP and General Manager of Global Sales | ||
| Henri Termeer, Independent Director | ||
| Thorsten Siess, Ex Officer | ||
| William Bolt, Sr. VP of Global Product Operations | ||
| Ingrid Goldberg, Director - Investor Relations | ||
| Matthew Plano, Ex Integration | ||
| Dorothy Puhy, Lead Independent Director | ||
| Michael Tomsicek, CFO, Vice President Treasurer | ||
| Sarah Karr, Communications Mang | ||
| Marc Began, Gen VP | ||
| Eric Rose, Director | ||
| Gerald Austen, Independent Director |
ABIOMED Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ABIOMED a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0955 | |||
| Profit Margin | 0.25 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 16.32 B | |||
| Shares Outstanding | 45.09 M | |||
| Shares Owned By Insiders | 2.02 % | |||
| Shares Owned By Institutions | 97.00 % | |||
| Number Of Shares Shorted | 753.62 K | |||
| Price To Earning | 76.38 X |
Pair Trading with ABIOMED
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ABIOMED position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ABIOMED will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to ABIOMED could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ABIOMED when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ABIOMED - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ABIOMED to buy it.
The correlation of ABIOMED is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ABIOMED moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ABIOMED moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ABIOMED can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in ABIOMED Stock
If you are still planning to invest in ABIOMED check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ABIOMED's history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |